# A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

> **NCT06524635** · PHASE2 · RECRUITING · sponsor: **AbbVie** · enrollment: 60 (estimated)

## Conditions studied

- Hidradenitis Suppurativa
- Atopic Dermatitis

## Interventions

- **DRUG:** Lutikizumab

## Key facts

- **NCT ID:** NCT06524635
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-14
- **Primary completion:** 2027-02
- **Final completion:** 2027-02
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06524635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06524635, "A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06524635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*